

Purpose

To recommend clinical preventive medicine services for adult patients in the primary care setting for better health outcomes.

Key Message for Healthy Aging

Clinical preventive services are important tools for healthy aging that can lower health risks and prevent or delay the onset of disease. Fewer than twenty-five percent of adults aged 50 to 64 years are up to date on services. Fewer than 50% of adults aged 65 years or older are up-to-date with core preventive services despite regular checkups.



| HEALTH PROMOTION SERVICE | RECOMMENDATION | SCREENING TEST |
|--|---|--|
| Health Assessment Screening, History and Counseling | A health maintenance visit every 1-3 yrs. for 19-49 yrs, according to risk status. Age 50-64 every 1-3 years based on need, then annually thereafter at age 65+ Each exam may include: • Height, weight and body mass index (BMI) • Risk evaluation and/or counseling Accidental Injury Prevention Alcohol/drug/opioid abuse screening Medication Reconciliation Blood pressure Obesity Calcium supplement as necessary Dental health Physical Activity • Assessment areas for those >65 yrs: Sodium restriction; social supports; polypharmacy including over the counter and herbal preparations; hypothyroidism; foot care; dental care; environment support; functional assessment like Activities of Daily Living (ADLs) i.e. feeding, dressing, grooming or Instrumental ADLs i.e. cooking, climbing stairs, etc. Encourage periodic eye exam by specialist and ask about hearing. Counsel as appropriate. | |
| Abdominal Aortic Aneurysm | At 65-75 yrs, one time screening by ultrasonography for men who have ever smoked. | Abdominal ultrasonography |
| Advance Care Planning/Health Care Proxy | Recommend completion of health care proxy >18 yrs; additional advance care directives (MOLST) as needed. | |
| Aspirin Prophylaxis | Counsel men 45-79 yrs, and women 55-79 yrs, based on assessment of risks and benefits. | |
| Breast Cancer Screening | Every 1-2 yrs for women 40-74 yrs and 40-49 yrs on different schedule based on discussion with patient. If women >74 yrs, make decision on a case-by-case basis. | |
| Cervical Cancer Screening | Screen women 21 to 65 yrs with cytology every 3 yrs. Screen women 30 to 65 yrs with a combination of cytology and HPV testing every 5 yrs (this method is for those who want to lengthen the screening interval to 5 yrs instead of 3 yrs). >65 yrs, screen women who had CIN2 or greater in the previous 20 yrs (or without adequate documentation of prior negative screening. | cytology or combination of cytology and HPV |
| Colorectal Cancer Screening | Screen between 50–75 yrs. Screening after age 75 is made on an individual basis. Cost effectiveness is an important consideration in ordering these tests; in most situations, the first three modalities listed here are currently the most cost-effective. | Screen using any of the following modalities including:: • high-sensitivity FOBT or FIT every 1 yr • sigmoidoscopy every 5 yrs • colonoscopy every 10 yrs • CT colonography • Fecal DNA |
| Depression Screening | Screen for depression when staff assisted supports in place to assure accurate diagnosis, effective treatment, and follow up. | Refer to MCMS Community-wide Guideline for Major Depressive Disorder |
| Diabetes Screening for Type 2 | Testing to detect type 2 diabetes and prediabetes in asymptomatic people should be considered in adults of any age who are overweight or obese (BMI ≥25 kg/m2*) or Asian Americans with BMI ≥ 23 kg/m2 and who have one or more additional risk factors for diabetes. *At-risk BMI may be lower in some ethnic groups. In those without risk factors, testing should begin at age 45 yrs. | Three tests have been used to screen for diabetes: Fasting plasma glucose (FPG) 2-hour post load plasma Hemoglobin A1c Refer to the MCMS Community-wide Guideline for Adult Diabetes Care |
| Fall Prevention | Assess and counsel those at high risk. | |



| HEALTH PROMOTION SERVICE | RECOMMENDATION | SCREENING TEST |
|---------------------------|--|--|
| Hepatitis C | Offer a one-time screening for HCV infection to adults born between 1945 – 1965. Screen for hepatitis C virus (HCV) infection in persons at high risk for infection. | Enzyme immunoassay (refer to Appendix A for recommended testing sequence) |
| Hypertension | Screen adults aged 40 years or older and those who are at increased risk for high blood pressure. Persons at increased risk include those who have high-normal blood pressure (130 to 139/85 to 89 mm Hg), those who are overweight or obese, and African Americans. Adults aged 18 to 39 years with normal blood pressure (<130/85 mm Hg) who do not have other risk factors should be rescreened every 3 to 5 years. | Refer to MCMS Community-wide Guideline for Management of Adult Hypertension. |
| Lipid Screening | Screen men >35 yrs. If at increased risk for CHD, screen women and men > 20 yrs. Increased risk = diabetes; tobacco use, hypertension, obesity, previous personal hx; family hx (e.g. cardiovascular disease in male relative < 50 yrs or in female relative <60 yrs). Once screening begins, screen every 5 yrs for low risk; more frequent for high risk. The National Heart Lung, Blood Institute and AAP recommend universal cholesterol screening between 9-11 yrs and again between 18-21 years. The AAP and NHLBI recommend that cardiovascular risk be assessed at other ages between 2-21 and recommend risk-based cholesterol screening if one or more risk factors are present. The USPSTF concludes evidence is insufficient to recommend for or against routine screening for lipid disorders in infants, children, adolescents & young adults to age 20. | |
| Lung Cancer Screening | Pa Patient Eligibility: 1) Age 55-80 (55-77 for Medicare) 2) Current smokers and former smokers who quit within 15 years 3) ≥30 pack years of smoking | Refer to MCMS Community-wide Guideline for Lung Cancer Screening |
| Osteoporosis Screening | Screen women aged 65 yrs or older. Screen women under 65 whose fracture risk is equal to or greater than that of a 65-year-old white woman who has no additional risk factors. | Screen using dual-energy x-ray absorptiometry (DEXA) of the hip and lumbar spine |
| Prostate Cancer Screening | Discuss pros and cons of screening for 50-75 yrs. Offer PSA & DRE if patient requests. | PSA and DRE |
| STI Screenings | | |
| Gonorrhea, Chlamydia | Screen all sexually active women, including those who are pregnant, if they are at increased risk for infection. Screen sexually active MSM at least annually. | For females, self-collected vaginal swabs are the specimen of choice for NAAT For males, first-catch urine is the specimen of choice for gonorrhea/chlamydia NAAT |
| Genital Herpes | Type-specific HSV serologic testing should be considered for men/women presenting for an STD evaluation (especially for men/women with multiple sex partners) Evidence does not support routine HSV-2 serologic screening among asymptomatic adolescents and adults, including those who are pregnant. However, type-specific serologic tests might be useful for identifying pregnant women at risk for HSV infection and guiding counseling regarding the risk for acquiring genital herpes during pregnancy. | Type-specific serological tests |
| HIV | Screening for patients <65 yrs. Preexposure prophylaxis (PrEP) of HIV in high risk patients. | First, enzyme immunoassay (EIA) or Rapid HIV antibody test In both tests, you can use blood, oral fluid, or urine Second, a confirmatory western blot or immunofluorescent assay |
| Syphilis, Hepatitis B | Screen for those at increased risk, and all pregnant women. | Two-step process involving initial nontreponmal test (VDRL) or RPR), followed by a confirmatory treponemal test (FTA-Abs or TPPA) |



| Tobacco Use | Screen for tobacco use and offer interventions (counseling, pharmacotherapy) for those who use tobacco products. Advise electronic cigarette (e-cigarette) products are not yet regulated by the US Food and Drug Administration and no rigorous scientific studies have shown that they are safe for use or effective in helping to quit smoking. | Ask (part of the 5 A's) every patient about tobacco use Refer to the <u>MCMS Community-wide Guideline for Treating Tobacco Use and Dependence</u> |
|--------------------------|---|---|
| Tuberculosis | Screen those at increased risk. | Tuberculin skin test (if positive, do chest X-ray) |
| Vitamin D Deficiency | Do not screen for vitamin D deficiency in healthy adults or children. On a case-by-case basis, consider selective testing for vitamin D deficiency in high-risk individuals such as patients with malabsorption syndromes | Serum 25-hydroxyvitamin D test Refer to the <u>MCMS Community-wide Guideline for Vitamin D Screening</u> |
| Other Things to Consider | Psychological trauma (associated with substance abuse, etc.), gun safety, seat belts, bike helmets, literacy | |

| IMMUNIZATIONS FOR UP-TO-DATE RECOMMENDATIONS CONSULT ACIP WEBSITE - <u>www.cdc.gov/vaccines/acip/index.html</u> |
|---|
|---|

Measures Commonly Used by National Organizations

- Breast Cancer Screening: 1) Percentage of women 40-69 years of age who had a mammogram to screen for breast cancer. (CMS Meaningful Use); 2) Percentage of women 50 through 74 years of age who had a mammogram to screen for breast cancer within 27 months (PQRS)
- Colorectal Cancer Screening: Percentage of adults 50-75 years of age who had appropriate screening for colorectal cancer. (PQRS/CMS Meaningful Use)
- Screening or Therapy for Osteoporosis for Women Aged 65-85: Percentage of female patients aged 65-85 years of age who ever had a central dual-energy X-ray absorptiometry (DXA) to check for osteoporosis (*PQRS*)
- Screening for Future Fall Risk Description: Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period. (CMS Meaningful Use)

High Risk Populations/Disparities

- In Monroe County, the prevalence of being obese or overweight is highest in blacks (68%) followed by whites (61%) and Latino residents (61%). (1)
- In Monroe County, in 2013-14, 30% of all adults have high blood pressure Rates are higher among Black (43%) compared to White (31%) residents.
- STD rates in Monroe County are higher than rates in NYS. Most STD cases occur among African American and Latino youth and young adults, who reside in the City.
 - o In 2014, Chlamydia case rate per 100,000 women, ages 15-44 years was 1715 in Monroe County compared to 1536 in NYS.
 - o In 2014, gonorrhea case rate per 100,000 women Ages 15-44 years was 330 in Monroe County compared to 165 in NYS.
 - o In 2014 gonorrhea case rate per 100,000 men ages 15-44 years was 368 in Monroe County compared to 303 in NYS.
 - The incidence rate of HIV in Monroe County (9.1%) is lower than NYS (17.9%). Rates in Monroe County are higher among Black (26.8%) and Latino (23.6%) residents compared to White residents (3.3).(3)
- In Monroe County, the percentage of Monroe County adults aged 18 years or older who are current cigarette smokers in 2013-14 is 15%. The rate is higher among Black (23%) (1) compared to White (15%) residents.

Health Maintenance Checklist for <u>HEALTHY WOMEN</u> 19 Years and Older

DOB: -Name:

| Name. | | DOB. — | | <u>.</u> | |
|-------------------------------------|---|--------|------|----------|------|
| COUNSELING/SCREENING | FREQUENCY | DATE | DATE | DATE | DATE |
| Age appropriate history & physical | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Alcohol misuse – screen, counsel | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Advance directives – counsel | At >18, and as needed | | | | |
| Calcium – assess, encourage | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Dental health – counsel | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Depression screening | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Diet/nutrition – counsel or refer | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Physical Activity - counsel | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Folate – encourage | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Injury prevention - counsel | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Obesity – counsel or refer | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Sexual health - counsel | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | 1 | |
| Tobacco Use – screen, counsel | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| IMMUNIZATIONS | | | | | |
| Human papillomavirus (HPV) | 19-26 yrs 3 doses | | | | |
| Influenza | Q 1 yr for all adults | | | | |
| Meningococcal | 1 or more doses if higher risk | | | | |
| MMR - if no evidence immunity | 1 -2 doses<50 yrs, 1 dose if increased risk & >50 yrs | | | 1 | |
| Pneumococcal vaccine | Pneumococcal vaccine-naïve persons ≥ 65 yrs: PCV13 at ≥ | | | | |
| (Sequential administration & | 65 yrs; f/u PPSV23, 6-12 mos later* | | | | |
| recommended intervals for PCV13 | PPSV23 already rec'd at ≥ 65 yrs: PCV13 ≥1 yrs since | | | | |
| & PPSV23 – CDC/ACIP, Sept | dose of PPSV23 | | | | |
| 2014) | • PPSV23 rec'd <65 yrs, persons now ≥ 65 yrs: PCV13 ≥ 1 | | | | |
| | yrs since dose of PPSV23; f/u PPSV23, 6-12 mos later* | | | | |
| Tetanus-diphtheria (TD) / Tdap | Routine use of PCV13 for ≥ 19 yrs at increased risk Substitute 1 time dose of Tdap for TD; boost Q 10 yr – TD; | | | + | |
| retanus-dipritrieria (TD) / Tdap | ≥65 yrs Td (Tdap) if contact w/<12 mo. child. Td or Tdap can | | | | |
| | be used if no infant contact | | | | |
| Varicella - if no evidence immunity | 2 doses 4-8 wks apart | | | | |
| Zoster | 1 dose ≥ 60 yrs | | | | |
| PROPHYLAXIS | | | | | |
| Aspirin – Discuss to prevent stroke | If at increased risk of stroke | | | | |
| TESTS/EXAMS | | | | | |
| Breast cancer screening | Q 1-2 40-74 yrs; >74 yrs as needed | | | | |
| Blood pressure | Q 2 yrs | | | | |
| Cervical cancer screening | Q3 21-65 yrs. w/cytology or Q5 30-65 yrs w/cytology &HPV | | | | |
| l common common g | >65 >CIN2 in last 20 yrs or w/out documentation of negative | | | | |
| | screening | | | | |
| Colorectal cancer screening | 50-75 yrs frequency varies with test selected; >75 individual | | | | |
| Diahataa | basis December sink | | | | |
| Diabetes Gonorrhea, Chlamydia | Based on risk Screen all sexually active women, including those who are | | | | |
| Conomiea, Omaniyala | pregnant if at increased risk | | | | |
| Hearing impairment | ≥65 yrs | | | | |
| Height & weight, BMI | 19-49 yrs Q 1-3yrs; 50+ yrs Q1 | | | | |
| Hepatitis C | Based on risk | | | | |
| HIV screening | <65 yrs | | | | |
| Lipids screening | Q 5 ≥ 20 yrs & at increased risk | | | | |
| Osteoporosis screening | ≥65 yrs; post menopausal if increased risk | | | | |
| Other STI testing | Based on risk | | | | |
| TB testing (PPD) | Based on risk | | | | |
| Visual impairment | ≥65 yrs | | | | |
| | 1 | 1 | 1 | 1 | 1 |

^{*} Minimum interval between sequential administration of PCV13 and PPSV23 is 8 wks; PPSV23 can be given later than 6-12 mos after PCV13 if this window is missed.

Health Maintenance Checklist for <u>HEALTHY MEN</u> 19 Years and Older

| Jame: | DOB: |
|-------|------|
| | |

| Counseling/Screening | FREQUENCY | DATE | DATE | DATE | DATE |
|--|---|-------|-------|-------|-------|
| Age appropriate history & physical | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | 27.12 | 27112 | 27112 | 27.12 |
| Alcohol misuse – screen, counsel | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Advance directives – counsel | At >18, and as needed | | | | |
| Calcium – assess, encourage | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Dental health – counsel | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Depression screening | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Diet/nutrition – counsel or refer | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Physical Activity - counsel | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Injury prevention - counsel | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Obesity – counsel or refer | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Sexual health - counsel | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Tobacco Use – screen, counsel | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| IMMUNIZATIONS | | | | | |
| Human papillomavirus (HPV) | 19-26 yrs 3 doses | | | | |
| Influenza | Q 1 yr for all adults | | | | |
| Meningococcal | 1 or more doses if higher risk | | | | |
| MMR - if no evidence immunity | 1 -2 doses<50 yrs, 1 dose if increased risk & >50 yrs | | | | |
| Pneumococcal vaccine (Sequential administration & recommended intervals for PCV13 & PPSV23 –CDC/ACIP, Sept 2014) | Pneumococcal vaccine-naïve persons ≥ 65 yrs: PCV13 at ≥ 65 yrs; f/u PPSV23, 6-12 mos later* PPSV23 already rec'd at ≥ 65 yrs: PCV13 ≥1 yrs since dose of PPSV23 PPSV23 rec'd <65 yrs, persons now ≥ 65 yrs: PCV13 ≥ 1 yrs since dose of PPSV23; f/u PPSV23, 6-12 mos later* Routine use of PCV13 for ≥ 19 yrs at increased risk | | | | |
| Tetanus-diphtheria (TD) / Tdap | Substitute 1 time dose of Tdap for TD; boost Q 10 yr − TD; ≥65 yrs Td(Tdap) if contact w/<12 mo. child. Td or Tdap can be used if no infant contact | | | | |
| Varicella - if no evidence immunity | 2 doses 4-8 wks apart | | | | |
| Zoster | 1 dose <u>></u> 60 yrs | | | | |
| PROPHYLAXIS | | | | | |
| Aspirin – Discuss to prevent stroke | If at increased risk of stroke | | | | |
| Testing/Exams | | | | | |
| AAA | Once, 65-75 yrs if ever smoked | | | | |
| Blood pressure | Q 2 yrs | | | | |
| Colorectal cancer | 50-75 yrs frequency varies with test selected; >75 individual basis | | | | |
| Diabetes | Based on risk | | | | |
| Gonorrhea, Chlamydia | At least Q 1 | | | | |
| Hearing impairment | ≥65 yrs | | | | |
| Height & weight, BMI | 19-49 yrs Q 1-3 yrs; 50+yrs Q1 | | | | |
| Hepatitis C | Based on risk | | | | |
| HIV | <65 yrs | | | | |
| Lipids | Q 5 ≥ 20 yrs & at increased risk | | | | |
| Other STI testing | Based on risk | | | | |
| Prostate cancer | 50-70 yrs; discuss known harms & potential benefits & offer PSA or DRE if patient requests | | | | |
| TB testing (PPD) | Based on risk | | | | |
| Visual impairment | ≥65 yrs | | | | |

^{*} Minimum interval between sequential administration of PCV13 and PPSV23 is 8 wks; PPSV23 can be given later than 6-12 mos after PCV13 if this window is missed.



Resources for Physicians

Center for Disease Control and Prevention

- <u>CDC Vaccine Schedules App for Clinicians and Other Immunization Providers</u> The app visually mimics the printed schedules, reviewed and published annually. Users can identify correct vaccine, dosage, and timing with 2 or 3 clicks. Any changes in the schedules will be released through app updates.
- <u>CDC Immunization Schedules to Display on Website</u> CDC immunization schedule and footnotes display within your web page.

Center for a Tobacco-Free Finger Lakes

Provides free "Tobacco Dependence Treatment: Train the Trainer" presentation for office champions and provide access to evidence-based resources and programs to assist providers in the design and implementation of office-based systems that identify and effectively treat tobacco dependence in Chemung, Livingston, Monroe, Seneca, Ontario, Seneca, Schuyler, Steuben, Wayne, and Yates Counties (585)275-0598.

New York State's Refer-To-Quit Program

Provides program for physician to help their patients stop smoking. Confidential coaching and cessation-related services are offered to patients who use tobacco products.

• Refer-To-Quit Program

Opt-to-Quit (policy based, EMR strategy)

• Fax Referral Program

Online Referral Form

Order materials for physicians to use with patients



Resources for Patients

Agency for Healthcare Research and Quality

(Order pamphlets - free order limit 200)

- Men: Stay Healthy at Any Age (Provides information to help men stay healthy at any age.)
- Men: Stay Healthy at Any Age (In Spanish)
- Men: Stay Healthy at 50+ (Provides information to help women stay healthy at age 50 and above.)
- Men: Stay Healthy at 50+ (In Spanish)
- Women: Stay Healthy at Any Age 2014 Update (Provides information to help women stay healthy at any age.)
- Women: Stay Healthy at Any Age 2014 Update (In Spanish)
- Women: Stay Healthy at 50+ (Provides information to help women stay healthy at age 50 and above.)
- Women: Stay Healthy at 50+ (In Spanish)

Healthfinder.gov

• Tips to be physically active and make healthy food choices.

Healthy Living Center - Stop Smoking Program

https://www.urmc.rochester.edu/community-health/programs-services/healthy-living-center.aspx

Provides evidence based intensive intervention with counseling and medication support in person to individuals, over 4 to 8 visits, living in Monroe County and the surrounding areas (585) 530-2050 FAX (585) 530-2398.

National Cancer Institute

- Order pamphlet: Clearing the Air: Quit Smoking Today (free-order limit 50) Describes tools that can help smokers stop smoking and the problems to expect when they quit.
- Order free pamphlet: Clear Horizons Self-help manual for smokers age 50 and older.

Smokefree.gov

Provides online resources to help patients quit smoking. Smartphone apps are user friendly and easy to download.

- <u>Download free QuitGuide Smartphone Apps</u> (designed to help patients prepare to quit smoking and support efforts)
- Download free QuitStart Smartphone Apps (created with teens in mind, but can be used by adults)
- <u>SmokefreeTXT</u> (free interactive text messaging to help adults and young adults quit smoking) https://smokefree.gov/tools-tips/smokefreetxt-signup



References

1. Health Reports/Health Action. Monroe County Health Data. Retrieved from Expanded Break Risk Factor Surveillance System (Expanded BRFSS), 2013-2014, NYS DOH

http://www.health.ny.gov/statistics/brfss/expanded/2013/county/

2. NYS STD Surveillance System as of March 2016, 2014 Available from: https://www.health.ny.gov/statistics/diseases/communicable/std/

3. Bureau of HIV/AIDS Epidemiology data as of April 2016, 2012-2014. Rates per 100,000 https://apps.health.ny.gov/doh2/applinks/ebi/SASStoredProcess/guest? program=%2FEBI%2FPHIG%2Fapps%2F dashboard%2Fpa dashboard&p=ch&cos=26

American Cancer Society (ACS), the American Society for Colposcopy and Cervical Pathology (ASCCP), and the American Society for Clinical Pathology (ASCP). https://www.hpv16and18.com/hcp/cervical-cancer-screening-guidelines/asccp-guidelines.html

Centers for Medicare & Medicaid Services Meaningful Use Quality Measure. (clinical quality measures for electronic submission by Medicare and Medicaid eligible physicians), Baltimore, MD. http://www.cms.gov/Regulations-and-

<u>Guidance/Legislation/EHRIncentivePrograms/index.html?redirect=/EHRIncentivePrograms/</u>

Centers for Medicare & Medicaid Services Physician Quality Reporting System (PQRS), Baltimore, MD. http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PORS/index.html?redirect=/pars

Clinical Preventive Services. American Academy of Family Practitioners. http://www.aafp.org/patient-care/clinical-recommendations/cps.html

Diseases and Conditions. Centers for Disease Control and Prevention. http://www.cdc.gov/

Health Care Guideline: Preventive Services for Adults. Institute for Clinical Systems Improvement. Twentieth Edition/October 2014 JAMA

https://www.icsi.org/guidelines more/catalog guidelines and more/catalog guidelines/catalog prevention screening guidelines/preventive services for adults/

JAMA: Screening for Colorectal Cancer and Evolving Issues for Physicians and Patients – A Review (Liberman, et al., November 22/29, 2016, Volume 316, Number 20, pp. 2135-2145)

JAMA: US Preventive Services Task Force Evidence Report; JAMA, 2016:316(23):2531-2543. doi:10.100/JAMA2016.17138

http://jamanetwork.com/journals/jama/fullarticle/2593576

JAMA: US Preventive Services Task Force Recommendation Statement: JAMA December 20, 2016 Volume 316, Number 23 (Force, 2016)


http://jamanetwork.com/journals/jama/fullarticle/2593575

USPSTF A-Z Topic Guide. U.S. Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/uspstopics.htm

Vaccines and Immunizations. Centers for Disease Control and Prevention. http://www.cdc.gov/vaccines/?s_cid=cdc_homepage_topmenu_002



Recommended Testing Sequence for Identifying Current HCV Infection



^{*} For persons who might have been exposed to HCV within the past 6 months, testing for HCV RNA or follow-up testing for HCV antibody is recommended. For persons who are immunocompromised, testing for HCV RNA can be considered.

Source: CDC. Testing for HCV infection: An update of guidance for clinicians and laboratorians. MMWR 2013;62(18). Available from: http://www.cdc.gov/hepatitis/HCV/Index.htm

To differentiate past, resolved HCV infection from biologic false positivity for HCV antibody, testing with another HCV antibody assay can be considered. Repeat HCV RNA testing if the person tested is suspected to have had HCV exposure within the past 6 months or has clinical evidence of HCV disease, or if there is concern regarding the handling or storage of the test specimen.